Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06496620 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
A Phase 2 study of COPD, sponsored by Uniquity One (UNI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
- 20
- Study locations
NCT06496620 is a Phase 2 study of COPD that is actively recruiting participants, run by Uniquity One (UNI). The registered enrollment target is 171 participants, below the 2,416-participant average among 85 other COPD trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT06496620, a Phase 2 study of COPD, is actively recruiting participants, sponsored by Uniquity One (UNI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Biological: Solrikitug low dose
- BIOLOGICAL Biological: Solrikitug high dose
Study Locations (20)
California
- Antelope Valley Clinical Trials - Lancaster
- Ark Clinical Research - Ballinger - Long Beach
- Downtown LA Research Center, Inc. - Los Angeles
- Newport Native MD, Inc. - Newport Beach
- OM Research - Oxnard
- Prospective Research Innovations, Inc. - Rancho Cucamonga
Florida
- Access Research Institute - Brooksville
- Innovative Research of West Florida, Inc. - Clearwater
- Clinical Research of West Florida - Clearwater - Clearwater
- JY Research Institute - Cutler Bay
- Hillcrest Medical Research, LLC - DeLand
- North Florida Foundation for Research and Education - Gainesville
Arizona
- Phoenix Medical Group - Peoria
- Epic Medical Research-Surprise - Sun City
- Alliance for Multispecialty Research - Tempe
- Novak Clinical Research - Tucson
Alabama
- University of Alabama at Birmingham Hospital - Birmingham
- Syed Research Consultants - Sheffield
Colorado
- Velocity Clinical Research - Denver - Englewood
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06496620
The ClinicalTrials.gov registry entry for NCT06496620 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,416-participant average among 85 other COPD trials with a reported enrollment target (93% lower). The listed sponsor is Uniquity One (UNI), which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06496620 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06496620 about?
NCT06496620 is a clinical study titled "A Study to Evaluate Solrikitug in Participants With COPD (ZION)". A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
What is the current status of trial NCT06496620?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2024-08-14. Estimated completion is 2026-10-31.
What conditions does trial NCT06496620 study?
This clinical trial studies the following conditions: COPD.
What interventions are being tested in trial NCT06496620?
The interventions under investigation include: Placebo (OTHER), Biological: Solrikitug low dose (BIOLOGICAL), Biological: Solrikitug high dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT06496620?
This trial is sponsored by Uniquity One (UNI), which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06496620 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
RECRUITING · Phase 2
-
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
COMPLETED · Phase 2
-
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.